# AtriCure

Type: Company (ATRC)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/atricure
Canonical HTML page: https://getbiobrief.com/entity/atricure

## Recent coverage (2 stories)

### DAFNA Capital Trims Axogen Stake Following 71% Rally and 20% Revenue Growth
2026-03-22 04:25:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
Full story: https://getbiobrief.com/story/dafna-capital-trims-axogen-stake-71-surge

### MedTech Resilience: Insulet and AtriCure Outperform Q4 Earnings Expectations
2026-02-18 19:19:07 · Sentiment: Positive · Impact: 6/10 · Sources: 6

Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Full story: https://getbiobrief.com/story/medtech-earnings-insulet-atricure-q4-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.